Suggested remit: To appraise the clinical and cost effectiveness of pembrolizumab with platinum-based chemotherapy within its marketing authorisation for unresectable locally advanced or metastatic oesophageal cancer that has not been previously treated.
Status In progress
Process STA 2018
ID number 3741

Provisional Schedule

Committee meeting: 1 03 August 2021
Expected publication 13 October 2021
Invitation to participate 23 November 2021

Project Team

Project lead Thomas Feist

Email enquiries

Evidence Review Group / Assessment Group Peninsula Technology Assessment Group (PenTAG), University of Exeter


Companies sponsors Merck Sharp and Dohme
Professional groups Association of Cancer Physicians
  Cancer Research UK
  Royal College of Physicians
  Royal College of Radiologists


General commentators All Wales Therapeutics and Toxicology Centre
  British National Formulary
  Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
  Medicines and Healthcare products Regulatory Agency
  Scottish Medicines Consortium
  Welsh Health Specialised Services Committee
Relevant research groups Institute of Cancer Research


Key events during the development of the guidance:

Date Update
22 September 2020 - 20 October 2020 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators
08 June 2020 Please note that following on from advice received from the company, the timelines for this appraisal have been revised and the appraisal is now anticipated to begin during mid-November 2020. These timings are based on a request from the company to reschedule the initial date set by NICE, in order to facilitate a suitably comprehensive and robust evidence submission.
29 January 2020 In progress. Topic is in progress

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance